We are live on ! Find out more
IPXL

Impax Laboratories, Inc.
IPXL

Delisted

IPXL was delisted on the 4th of May, 2018.

185 hedge funds and large institutions have $1.85B invested in Impax Laboratories, Inc. in 2014 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 66 increasing their positions, 72 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

28% more capital invested

Capital invested by funds: $1.45B → $1.85B (+$402M)

16% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 25

2% more funds holding

Funds holding: 181185 (+4)

8% less repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 72

32% less call options, than puts

Call options by funds: $3.56M | Put options by funds: $5.24M

Holders
185
Holders Change
+4
Holders Change %
+2.21%
% of All Funds
5.31%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
29
Increased
66
Reduced
72
Closed
25
Calls
$3.56M
Puts
$5.24M
Net Calls
-$1.68M
Net Calls Change
-$5.12M
Name Holding Trade Value Shares
Change
Change in
Stake
VOYA Investment Management
26
VOYA Investment Management
Georgia
$17.7M -$1.97M -72,920 -11%
Massachusetts Financial Services
27
Massachusetts Financial Services
Massachusetts
$16.8M +$5.83M +215,983 +63%
PHS
28
PFM Health Sciences
California
$16M +$14.4M +534,228 New
JP Morgan Chase
29
JP Morgan Chase
New York
$15.5M +$7.75M +287,170 +125%
PC
30
PointState Capital
New York
$15M +$4.05M +150,000 +43%
PI
31
Putnam Investments
Massachusetts
$14.4M -$189K -7,007 -1%
TSW
32
Thompson Siegel & Walmsley
Virginia
$12.6M +$11.4M +421,581 New
Principal Financial Group
33
Principal Financial Group
Iowa
$12.4M +$51K +1,890 +0.5%
TA
34
Teachers Advisors
New York
$11.8M +$251K +9,292 +2%
Acadian Asset Management
35
Acadian Asset Management
Massachusetts
$11.8M +$9.72M +360,341 +1,142%
Geode Capital Management
36
Geode Capital Management
Massachusetts
$11.7M +$134K +4,982 +1%
EAM
37
Eagle Asset Management
Florida
$10.5M -$1.52M -56,422 -14%
TCM
38
Tekla Capital Management
Massachusetts
$10.3M
Millennium Management
39
Millennium Management
New York
$10.1M -$22.8M -846,835 -71%
HSA
40
Hussman Strategic Advisors
Maryland
$9.3M +$2.43M +90,000 +41%
TCIM
41
TIAA CREF Investment Management
New York
$9.29M -$244K -9,044 -3%
CM
42
CS McKee
Pennsylvania
$9.21M -$1.51M -55,880 -15%
Wellington Management Group
43
Wellington Management Group
Massachusetts
$8.86M +$1.28M +47,619 +19%
TI
44
Turner Investments
Pennsylvania
$8.58M -$3.68M -136,250 -32%
Thrivent Financial for Lutherans
45
Thrivent Financial for Lutherans
Minnesota
$8.53M +$5.62M +208,249 +273%
Goldman Sachs
46
Goldman Sachs
New York
$8.34M +$2.09M +77,338 +39%
Charles Schwab
47
Charles Schwab
California
$7.78M -$13.2M -490,589 -65%
PAM
48
Panagora Asset Management
Massachusetts
$7.68M +$2.45M +90,729 +55%
ACH
49
ArrowMark Colorado Holdings
Colorado
$7.62M +$2.79M +103,477 +69%
ICAP
50
Independence Capital Asset Partners
Colorado
$7.59M +$2.8M +103,661 +69%

IPXL Hedge Fund Activity: Q2 2014 in Review

185 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Impax Laboratories, Inc. (IPXL) for Q2 2014, worth a combined $1.85B — up 28% from $1.45B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new IPXL positions and 25 closed out — a net gain of 4 holders — while 66 added to existing stakes and 72 trimmed.

The largest buyer was Invesco, adding an estimated $41.5M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $27.6M sold.

  • 185 institutional investors held Impax Laboratories, Inc. (IPXL) as of Q2 2014, up from 181 in Q1 2014.
  • Funds reported $1.85B of Impax Laboratories, Inc. stock for Q2 2014, up 28% quarter-over-quarter.
  • 29 funds opened new Impax Laboratories, Inc. positions in Q2 2014 and 25 closed out, a net change of +4 holders.
  • The largest Impax Laboratories, Inc. buyer in Q2 2014 was Invesco, an estimated $41.5M added.
  • The largest Impax Laboratories, Inc. seller in Q2 2014 was Renaissance Technologies, an estimated $27.6M sold.

Based on aggregated 13F filings for Q2 2014.